Member Info for ParanoiaBlue

DIY retailer Kingfisher saw third quarter retail profit fall 4% to £176m on flat retail sales of £2.6bn but down 5.1% on a like-for-like basis. In a weak UK market retail profit was down £9m to £36m while in a flat French market sales and retail profit both grew.

..........a pharma putting in a healthy performance!

....2 brokers now rate GFM "strong buy"

..to see a bit of "action" here, for a change.

I‘ve had a look at Vernalis - they appear to have a reasonable product pipeline, and their SP has halved in the last 6 months.

Let’s hope not, unless, it is a diamond-bearing mud! GFM hasn’t really been doing much for quite while. I was hoping for a reasonable rise by now.

...continued steady rise :) |

TEMPORARY SUSPENSION OF TRADING ON AIM VIANET GROUP PLC At the request of the company trading on AIM for the under-mentioned securities has been temporarily suspended from 24/11/2008 7:30am pending clarification of the company's financial position.

Scotsman: SHARES in Vianet, the Dunfermline-based data services firm, are due to be suspended from Aim this morning following a request from the firm's board. Earlier this month, Vianet borrowed £300,000 from Barkley Ltd, one of its investors. In a statement, Vianet's board said: "Long-running discussions with two separate parties have been terminated, as a result of which the directors now consider there is a serious risk that the company will be unable to continue to trade beyond the short term." Oh well, Monday morning blues!

Link: http://www.theherald.co.uk/business/news/display.var.2470150.0.Kingfisher_and_DSG_to_provide_more_grim_news.php

I think that the basic fundamentals suggest, take a punt, and there are a few spare paddles still on board [perhaps the wrong oar-type, but there will be rapids ahead to be manoeuvred]. OK, the downside could be bad – however the SP has held its head above the water, most of this year, so far – but you could get much more than just your feet wet. However, the upside is absolute “rocket material” if things work out! ATB

...on market drop, for £1K

@ 76.5p

With its merger with PTI – due to take effect on 4 December – its cash level will be well above £80m. Always an important factor, but, especially, at the moment!!

I.C. Update “BTG has started selling some of its pre-clinical research, which is also good news. Its shares are in line with our initial buy advice [154p 19 June 2008], but the benefits of the imminent merger [PTI] means they are still a buy.”

There is a presentation of data due in December, and the final data on its leukaemia treatment [AS1411] is due mid-2009.

“Antisoma is still highly speculative, but its cash pile of close to £E67m and its healthy pipeline gives us confidence that it will deliver for investors. At 21p, the shares are a buy.”

Link: http://www.investorschronicle.co.uk/MarketsAndSectors/Markets/article/20081120/2d5941bc-b63b-11dd-9511-00144f2af8e8/Hold-on-to-the-mining-giants.jsp I would concur with the sentiment of this article, but also included “small to mid” mining companies!

WE get BTG shares @ the rate: 1 PTI share = 0.291 BTG share.

Link: http://www.alizyme.com/alizyme/uploads/press/H2InterimManagementStatement2008Final.pdf Commenting on today’s announcement, Tim McCarthy, Alizyme’s Chief Executive Officer said: “We are advancing the development of our portfolio with strong support from our existing corporate partners and are progressing discussions in relation to the partnering and commmercialisation of the remaining licence rights to the products in our portfolio. Through further success in partnering, we are aiming to continue to build multiple revenue streams for Alizyme.”